Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study

References

• Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088–1095.
   PubMed Web of Science ®Google Scholar
• Delahoy MJ, Ujamaa D, Whitaker M, et al. Hospitalizations associated with COVID-19 among children and adolescents — COVID-NET, 14 states, March 1, 2020–August 14, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1255–1260.
   PubMed Web of Science ®Google Scholar
• Tso WWY, Kwan MYW, Wang YL, et al. Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections. Emerg Microbes Infect. 2022;11:1742–1750.
   PubMed Web of Science ®Google Scholar
• Taylor CA, Whitaker M, Anglin O, et al. COVID-19–associated hospitalizations among adults during SARS-CoV-2 delta and Omicron variant predominance, by race/ethnicity and vaccination status — COVID-NET, 14 states, July 2021–January 2022. Morb Mortal Wkly Rep. 2022;71:466.
   PubMed Web of Science ®Google Scholar
• Chua GT, Kwan MYW, Chui CSL, et al. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comirnaty vaccination. Clin Infect Dis. 2022;75(4):673–681.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Li X, Peng K, et al. Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: a case-control study. Ann Intern Med. 2022;175(3):362–370.
   PubMed Web of Science ®Google Scholar
• Cohen-Stavi CJ, Magen O, Barda N, et al. BNT162b2 vaccine effectiveness against Omicron in children 5 to 11 years of age. N Engl J Med. 2022;387:227–236.
   PubMedGoogle Scholar
• Price AM, Olson SM, Newhams MM, et al. BNT162b2 protection against the Omicron variant in children and adolescents. N Engl J Med. 2022;386:1899–1909.
   PubMed Web of Science ®Google Scholar
• Sacco C, Del Manso M, Mateo-Urdiales A, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022. Lancet. 2022;400:97–103.
   PubMed Web of Science ®Google Scholar
• Tan SHX, Cook AR, Heng D, et al. Effectiveness of BNT162b2 vaccine against Omicron in children 5 to 11 years of age. N Engl J Med. 2022;387:525–532.
   PubMedGoogle Scholar
• Florentino PTV, Alves FJO, Cerqueira-Silva T, et al. Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period. Nat Commun. 2022;13:4756.
   PubMed Web of Science ®Google Scholar
• Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. Nat Med. 2022;28:1377–1380.
   PubMed Web of Science ®Google Scholar
• Cheng FWT, Fan M, Wong CKH, et al. The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases. Kidney Int. 2022;102(4):922–925
   PubMed Web of Science ®Google Scholar
• Chui CSL, Fan M, Wan EYF. Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: a self-controlled case series study. eClinicalMedicine. 2022;50:101504.
   PubMedGoogle Scholar
• Lai FTT, Chua GT, Chan EWW, et al. Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. Emerg Microbes Infect. 2022;11:885–893.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Huang L, Chui CSL, et al. Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong. Nat Commun. 2022;13:411.
   PubMed Web of Science ®Google Scholar
• Leung TYM, Chan AYL, Chan EW, et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerg Microbes Infect. 2020;9:2190–2199.
   PubMed Web of Science ®Google Scholar
• Li X, Tong X, Yeung WWY, et al. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2022;81(4):564–568.
   PubMed Web of Science ®Google Scholar
• Li X, Gao L, Tong X, et al. Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: A descriptive cohort study among 1.1 million vaccinated people in Hong Kong. J Autoimmun. 2022;130:102830.
   PubMed Web of Science ®Google Scholar
• Sing CW, Tang CTL, Chui CSL, et al. COVID-19 vaccines and risks of hematological abnormalities: nested case-control and self-controlled case series study. Am J Hematol. 2022;97:470–480.
   PubMed Web of Science ®Google Scholar
• Wan EYF, Chui CSL, Lai FTT, et al. Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2022;22:64–72.
   PubMed Web of Science ®Google Scholar
• Wan EYF, Chui CSL, Wang Y, et al. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study. Lancet Reg Health West Pac. 2022;21:100393.
   PubMedGoogle Scholar
• Wan EYF, Wang Y, Chui CSL, et al. Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series. Lancet Healthy Longev. 2022;3:e491–e500.
   PubMedGoogle Scholar
• Wong CKH, Lau KTK, Xiong X, et al. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study. PLoS Med. 2022;19:e1004018.
   PubMed Web of Science ®Google Scholar
• Wong CKH, Mak LY, Au ICH, et al. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. J Hepatol. 2022;77:1339–1348.
   PubMed Web of Science ®Google Scholar
• Xiong X, Wong CKH, Au ICH, et al. Safety of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study. Thyroid. 2022;32(5):505–514.
   PubMed Web of Science ®Google Scholar
• Ye X, Ma T, Blais JE, et al. Association between BNT162b2 or CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with cardiovascular disease. Cardiovasc Res. 2022;118(10):2329–2338.
   PubMed Web of Science ®Google Scholar
• Huang YQ, Gou R, Diao YS, et al. Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. J Zhejiang Univ Sci B. 2014;15:58–66.
   PubMed Web of Science ®Google Scholar
• Miller TE, Garcia Beltran WF, Bard AZ, et al. Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. FASEB J. 2020;34:13877–13884.
   PubMed Web of Science ®Google Scholar
• Pearce N. Analysis of matched case-control studies. BMJ. 2016;352:i969.
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385:e83.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Barouch DH. T cell immunity to COVID-19 vaccines. Science. 2022;377:821–822.
   PubMed Web of Science ®Google Scholar
• Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996–1012.e19.
   PubMed Web of Science ®Google Scholar